Browse

VEGF polymorphisms in early cervical cancer susceptibility, angiogenesis, and survival

DC Field Value Language
dc.contributor.authorKim, Yun Hwan-
dc.contributor.authorKim, Min A.-
dc.contributor.authorPark, In-Ae-
dc.contributor.authorPark, Woong-Yang-
dc.contributor.authorKim, Seung Cheol-
dc.contributor.authorSong, Yong-Sang-
dc.contributor.authorKong, Soon-Beom-
dc.contributor.authorPark, Noh-Hyun-
dc.contributor.authorKim, Jae Weon-
dc.date.accessioned2012-05-31T02:06:20Z-
dc.date.available2012-05-31T02:06:20Z-
dc.date.issued2010-11-
dc.identifier.citationGYNECOLOGIC ONCOLOGY; Vol.119 2; 232-236ko_KR
dc.identifier.issn0090-8258-
dc.identifier.urihttps://hdl.handle.net/10371/76653-
dc.description.abstractObjective. Vascular endothelial growth factor (VEGF) plays an important role in cervical carcinogenesis. We hypothesized that VEGF genetic polymorphisms may affect cancer susceptibility, angiogenesis, and survival in patients with early cervical cancer. Methods. Among 215 healthy subjects and 199 early cervical cancer patients who were treated with surgical resection, we specifically investigated four genetic polymorphisms within the VEGF gene (-2578C>A, -460 T>C, +405G>C, and +936C>T). VEGF and CD31 microvessel density (MVD) were measured using tissue microarrays constructed from 117 patients who had available tissue. Results. Risk of cervical cancer was decreased in subjects with the VEGF -2578A/A genotype (adjusted OR = 0.39, 95% CI 0.16-0.96). Angiogenesis measured by CD31 MVD was significantly decreased in patients with the VEGF +405C/C genotype and VEGF -2578C - -460T - + 405C haplotype (recessive model; adjusted OR=0.32, 95% CI 0.11-0.99, equally). Moreover, VEGF +405C/C and VEGF -2578C - 460 T - +405C haplotype were significantly related to shorter disease-free survival (adjusted HR = 3.18, 95% CI 1.13-8.94, equally) and overall survival (adjusted HR=8.86, 95% CI 1.40-56.08, equally) by multiple Cox regression analysis. Conclusion. Polymorphisms of VEGF genes may affect cancer susceptibility and survival of early cervical cancer by modulating tumor angiogenesis. Prospective study among homogeneously treated patients is warranted. (C) 2010 Elsevier Inc. All rights reserved.ko_KR
dc.language.isoenko_KR
dc.publisherACADEMIC PRESS INC ELSEVIER SCIENCEko_KR
dc.subjectVEGFko_KR
dc.subjectPolymorphismko_KR
dc.subjectCervical cancerko_KR
dc.subjectSurvivalko_KR
dc.subjectAngiogenesisko_KR
dc.titleVEGF polymorphisms in early cervical cancer susceptibility, angiogenesis, and survivalko_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor김윤환-
dc.contributor.AlternativeAuthor김민아-
dc.contributor.AlternativeAuthor박인애-
dc.contributor.AlternativeAuthor박웅양-
dc.contributor.AlternativeAuthor김재원-
dc.contributor.AlternativeAuthor김승철-
dc.contributor.AlternativeAuthor박노현-
dc.contributor.AlternativeAuthor송용상-
dc.contributor.AlternativeAuthor공순범-
dc.identifier.doi10.1016/j.ygyno.2010.07.035-
dc.citation.journaltitleGYNECOLOGIC ONCOLOGY-
dc.description.citedreferenceRandall LM, 2009, GYNECOL ONCOL, V112, P583, DOI 10.1016/j.ygyno.2008.11.013-
dc.description.citedreferenceKim YT, 2009, J GYNECOL ONCOL, V20, P1, DOI 10.3802/jgo.2009.20.1.1-
dc.description.citedreferenceSchneider BP, 2008, BREAST CANCER RES TR, V111, P157, DOI 10.1007/s10549-007-9755-9-
dc.description.citedreferenceHofmann G, 2008, J CANCER RES CLIN, V134, P591, DOI 10.1007/s00432-007-0322-x-
dc.description.citedreferenceHeist RS, 2008, J CLIN ONCOL, V26, P856, DOI 10.1200/JCO.2007.13.5947-
dc.description.citedreferenceKim JG, 2008, CLIN CANCER RES, V14, P62, DOI 10.1158/1078-0432.CCR-07-1537-
dc.description.citedreferenceNASR HB, 2008, CLIN CHIM ACTA, V395, P124, DOI 10.1016/j.cca.2008.05.022-
dc.description.citedreferenceChen W, 2007, VIROLOGY, V367, P168, DOI 10.1016/j.virol.2007.05.030-
dc.description.citedreferenceKim JG, 2007, ANN ONCOL, V18, P1030, DOI 10.1093/annonc/mdm085-
dc.description.citedreferenceHefler LA, 2007, CLIN CANCER RES, V13, P898, DOI 10.1158/1078-0432.CCR-06-1008-
dc.description.citedreferenceTzanakis N, 2006, J SURG ONCOL, V94, P624, DOI 10.1002/jso.20619-
dc.description.citedreferenceAnderson JE, 2006, DRUG RESIST UPDATE, V9, P198, DOI 10.1016/j.drup.2006.08.001-
dc.description.citedreferenceLu H, 2005, CANCER RES, V65, P5015-
dc.description.citedreferenceParkin DM, 2005, CA-CANCER J CLIN, V55, P74-
dc.description.citedreferenceHicklin DJ, 2005, J CLIN ONCOL, V23, P1011, DOI 10.1200/JCO.2005.06.081-
dc.description.citedreferenceKoukourakis MI, 2004, LUNG CANCER-J IASLC, V46, P293, DOI 10.1016/j.lungcan.2004.04.037-
dc.description.citedreferenceToussaint-Smith E, 2004, ONCOGENE, V23, P2988, DOI 10.1038/sj.onc.1207442-
dc.description.citedreferenceStevens A, 2003, CANCER RES, V63, P812-
dc.description.citedreferenceLee IJ, 2002, INT J RADIAT ONCOL, V54, P768-
dc.description.citedreferenceBosch FX, 2002, J CLIN PATHOL, V55, P244-
dc.description.citedreferenceRenner W, 2000, J VASC RES, V37, P443-
dc.description.citedreferenceCarmeliet P, 2000, NATURE, V407, P249-
dc.description.citedreferenceWatson CJ, 2000, CYTOKINE, V12, P1232-
dc.description.citedreferenceFujiwaki R, 2000, ANTICANCER RES, V20, P1317-
dc.description.citedreferenceKodama J, 1999, EUR J CANCER, V35, P485-
dc.description.citedreferenceHanahan D, 1996, CELL, V86, P353-
dc.description.citedreferenceGUIDI AJ, 1995, J NATL CANCER I, V87, P1237-
dc.description.tc8-
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Pathology (병리학전공)Journal Papers (저널논문_병리학전공)
Files in This Item:
There are no files associated with this item.
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse